Evidence map›Paper›PMID 41847133›Full record

ArticleFrontiers in pharmacology2026

Celastrol increases anoikis sensitivity to suppress triple-negative breast cancer via EGFR pathway and p-EMT state regulation.

Jue Yang, Xiangpeng Wang, Xiuyun Bai, Rongjun Deng, Wanting Ye, Qiqiong Liu, Ying Xing, Yuxing Yao, Aiping Lyu, Cheng Lu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jue Yang *School of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Xiangpeng Wang *School of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Xiuyun BaiSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Rongjun DengSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Wanting YeSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Qiqiong LiuSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Ying XingSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Yuxing YaoSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Aiping LyuSchool of Chinese Medicine, Hong Kong Baptist University, Kowloon, China.
Cheng LuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Yuanyan LiuSchool of Materia Medica, Beijing University of Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Faced with the highly malignant threat of metastatic triple-negative breast cancer (TNBC), the effect of traditional chemical agents is limited, and new anti-metastasis drug remains to be explored. Celastrol (Cel) is a bioactive compound derived from

Indexed as

anoikiscelastrolcirculating tumor cellstriple-negative breast cancertumor metastasis

Identifiers

PMID41847133
PMCPMC12989539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.